The adenosine A 2B G protein-coupled receptor: Recent advances and therapeutic implications

Elizabeth A. Vecchio, Paul J. White, Lauren T. May

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

The adenosine A2B receptor (A2BAR) is one of four adenosine receptor subtypes belonging to the Class A family of G protein-coupled receptors (GPCRs). Until recently, the A2BAR remained poorly characterised, in part due to its relatively low affinity for the endogenous agonist adenosine and therefore presumed minor physiological significance. However, the substantial increase in extracellular adenosine concentration, the sensitisation of the receptor and the upregulation of A2BAR expression under conditions of hypoxia and inflammation, suggest the A2BAR as an exciting therapeutic target in a variety of pathological disease states. Here we discuss the pharmacology of the A2BAR and outline its role in pathophysiology including ischaemia-reperfusion injury, fibrosis, inflammation and cancer.

Original languageEnglish
Pages (from-to)20-33
Number of pages14
JournalPharmacology and Therapeutics
Volume198
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • adenosine A receptor
  • cancer
  • fibrosis
  • inflammation and immune response
  • ischaemia-reperfusion injury

Cite this

@article{07e712d55c71457cbc75153118ae31e5,
title = "The adenosine A 2B G protein-coupled receptor: Recent advances and therapeutic implications",
abstract = "The adenosine A2B receptor (A2BAR) is one of four adenosine receptor subtypes belonging to the Class A family of G protein-coupled receptors (GPCRs). Until recently, the A2BAR remained poorly characterised, in part due to its relatively low affinity for the endogenous agonist adenosine and therefore presumed minor physiological significance. However, the substantial increase in extracellular adenosine concentration, the sensitisation of the receptor and the upregulation of A2BAR expression under conditions of hypoxia and inflammation, suggest the A2BAR as an exciting therapeutic target in a variety of pathological disease states. Here we discuss the pharmacology of the A2BAR and outline its role in pathophysiology including ischaemia-reperfusion injury, fibrosis, inflammation and cancer.",
keywords = "adenosine A receptor, cancer, fibrosis, inflammation and immune response, ischaemia-reperfusion injury",
author = "Vecchio, {Elizabeth A.} and White, {Paul J.} and May, {Lauren T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.pharmthera.2019.01.003",
language = "English",
volume = "198",
pages = "20--33",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",

}

The adenosine A 2B G protein-coupled receptor : Recent advances and therapeutic implications. / Vecchio, Elizabeth A.; White, Paul J.; May, Lauren T.

In: Pharmacology and Therapeutics, Vol. 198, 01.01.2019, p. 20-33.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - The adenosine A 2B G protein-coupled receptor

T2 - Recent advances and therapeutic implications

AU - Vecchio, Elizabeth A.

AU - White, Paul J.

AU - May, Lauren T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The adenosine A2B receptor (A2BAR) is one of four adenosine receptor subtypes belonging to the Class A family of G protein-coupled receptors (GPCRs). Until recently, the A2BAR remained poorly characterised, in part due to its relatively low affinity for the endogenous agonist adenosine and therefore presumed minor physiological significance. However, the substantial increase in extracellular adenosine concentration, the sensitisation of the receptor and the upregulation of A2BAR expression under conditions of hypoxia and inflammation, suggest the A2BAR as an exciting therapeutic target in a variety of pathological disease states. Here we discuss the pharmacology of the A2BAR and outline its role in pathophysiology including ischaemia-reperfusion injury, fibrosis, inflammation and cancer.

AB - The adenosine A2B receptor (A2BAR) is one of four adenosine receptor subtypes belonging to the Class A family of G protein-coupled receptors (GPCRs). Until recently, the A2BAR remained poorly characterised, in part due to its relatively low affinity for the endogenous agonist adenosine and therefore presumed minor physiological significance. However, the substantial increase in extracellular adenosine concentration, the sensitisation of the receptor and the upregulation of A2BAR expression under conditions of hypoxia and inflammation, suggest the A2BAR as an exciting therapeutic target in a variety of pathological disease states. Here we discuss the pharmacology of the A2BAR and outline its role in pathophysiology including ischaemia-reperfusion injury, fibrosis, inflammation and cancer.

KW - adenosine A receptor

KW - cancer

KW - fibrosis

KW - inflammation and immune response

KW - ischaemia-reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=85061894811&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2019.01.003

DO - 10.1016/j.pharmthera.2019.01.003

M3 - Review Article

VL - 198

SP - 20

EP - 33

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -